BASIC INFORMATION

Date & Time: March 31, 2026, 12:54 PM (Indian Standard Time)

Lecture Handout Prepared from the Teaching Session by: Dr. R. K. Mishra

SUMMARY

This document summarizes a SAGES webinar on endobariatric alternatives to Roux-en-Y Gastric Bypass. The session provided a comprehensive overview of three primary endoluminal procedures: the intragastric balloon, duodenal mucosal resurfacing (DMR), and endoscopic sleeve gastroplasty (ESG). The lecture detailed the evolution, types, and procedural techniques for intragastric balloons, emphasizing the critical role of multidisciplinary follow-up and the emerging strategy of combination therapy with GLP-1 agonists. It then explored the scientific rationale for duodenal-targeted therapies, such as DMR, which aim to reverse metabolic dysfunction by ablating and regenerating the duodenal mucosa. Finally, the session covered ESG, a durable suturing procedure that remodels the stomach to create restriction and favorable metabolic changes, positioning it as a key intervention to bridge the treatment gap between medical management and traditional bariatric surgery. The overall theme emphasized a tailored, multi-modal approach to obesity management, leveraging these less invasive technologies to expand treatment access and improve patient outcomes.

KEY KNOWLEDGE POINTS

• The Obesity Treatment Gap: A significant disparity exists between the number of patients eligible for bariatric surgery and the low percentage who undergo it, creating a need for less invasive alternatives.

• Intragastric Balloons: These are temporary, space-occupying devices that induce early satiety. Their success is highly dependent on a structured, multidisciplinary follow-up program and can be enhanced with combination pharmacotherapy.

• Duodenal Mucosal Resurfacing (DMR): This is a metabolic procedure based on the "foregut hypothesis." It involves ablating the duodenal mucosa to allow for the regeneration of healthy tissue, thereby improving glycemic control and metabolic signaling independent of significant weight loss.

• Endoscopic Sleeve Gastroplasty (ESG): A durable, minimally invasive procedure that uses a full-thickness endoscopic suturing system to reduce gastric volume and create a restrictive sleeve, functionally mimicking a surgical sleeve gastrectomy without organ removal.

• Comparative Efficacy: Endobariatric procedures occupy a distinct place in the treatment algorithm. ESG demonstrates weight loss superior to medical management but less than formal bariatric surgery. DMR provides significant metabolic benefits.

• Combination Therapy: The future of obesity management lies in combining procedural interventions (like ESG or balloons) with pharmacotherapy (like GLP-1 agonists) to achieve synergistic effects on weight loss and maintenance.

• Technical Principles: Successful endobariatric procedures require specialized endoscopic skills, including one-handed scope manipulation for ESG and meticulous technique for balloon removal and DMR.

INTRODUCTION

The management of obesity and its related metabolic comorbidities is a central challenge in modern medicine. While traditional bariatric surgery, such as the Roux-en-Y Gastric Bypass, remains the gold standard for efficacy, its adoption is limited by patient fear, perceived invasiveness, and access barriers. This has created a significant treatment gap for millions of patients who require an intervention more effective than lifestyle modification or pharmacotherapy alone. Endobariatrics has emerged as a transformative field to bridge this gap, offering a portfolio of minimally invasive, endoluminal procedures.

This lecture provides a comprehensive review of three leading endobariatric alternatives: the intragastric balloon, duodenal mucosal resurfacing (DMR), and endoscopic sleeve gastroplasty (ESG). We will explore the mechanism of action, procedural principles, clinical evidence, and patient selection for each modality. The discussion will contextualize these tools within a modern, integrated framework for obesity care, highlighting their roles as standalone therapies, in combination with medication, and as a gateway to broader bariatric treatment.

LEARNING OBJECTIVES

• To understand the rationale, mechanism of action, and clinical applications for intragastric balloons, duodenal mucosal resurfacing, and endoscopic sleeve gastroplasty.

• To critically evaluate the efficacy and safety data for each procedure and compare their risk-benefit profiles relative to medical therapy and traditional bariatric surgery.

• To identify the core technical principles and surgical pearls for the safe and effective performance of these endobariatric interventions.

• To recognize the importance of a multidisciplinary approach, patient selection, and long-term follow-up in achieving successful outcomes with endobariatric therapies.

• To formulate a strategy for skill development in advanced endoscopy relevant to a modern bariatric and metabolic surgical practice.

CORE CONTENT

1. Webinar Overview and SAGES Introduction

• Title: Endobariatric Alternatives to Roux-en-Y Gastric Bypass.

• Organizing Body: SAGES (Society of American Gastrointestinal Endoscopic Surgeons) on behalf of the Residents and Fellows Training (RAFT) Committee.

• Moderators: Dr. Rodolfo Oviedo and Dr. Miquela Esquivel.

• Expert Faculty and Topics:

  • Intragastric Balloons: Dr. Manuel Galvão Neto.

  • Duodenal Mucosal Resurfacing: Dr. Adarsh Thacker.

  • Endoscopic Sleeve Gastroplasty (ESG): Dr. Brandon VanderWel and Dr. R.K. Mishra.

• SAGES Mission and Vision: The society is dedicated to innovating, educating, and collaborating to improve patient care, with a vision of reimagining surgical care for a healthier world. Membership provides access to education, a network of over 7,000 colleagues, research grants, and leadership opportunities.

2. Intragastric Balloon Therapy

2.1. Principles and Types

The intragastric balloon is a space-occupying device that induces early satiety. It is a temporary, reversible procedure.

• Traditional Liquid-Filled Balloons (e.g., Orbera®): Filled with 400-700 mL of saline (often with methylene blue). Requires endoscopy for placement and removal; indwelling for 6 months.

• Adjustable Balloons (e.g., Spatz3®): Allows for post-placement endoscopic volume adjustment to manage intolerance or enhance efficacy.

• Swallowable Balloons: A capsule is swallowed and inflated without endoscopy. A self-releasing valve opens after approximately 4 months, allowing the deflated balloon to be naturally excreted.

2.2. Operative Principles

• Insertion: Performed under conscious sedation. A diagnostic endoscopy is followed by passage of the collapsed balloon, inflation under direct vision, and confirmation of correct fundal positioning.

• Removal: Performed under general anesthesia with endotracheal intubation to protect the airway. The balloon is punctured, the fluid is aspirated, and the deflated shell is grasped and withdrawn. A final endoscopy inspects for mucosal injury.

2.3. Efficacy and Post-Procedural Management

• Efficacy: Real-world data (Brazilian consensus of >41,000 cases) shows a mean total body weight loss (TBWL) of 18.4%. RCTs show a range of 5-16% TBWL.

• Post-Procedure Adaptation: The first 3-5 days are critical. Management focuses on aggressive antiemetic therapy (e.g., aprepitant, dimenhydrinate) and proactive intravenous hydration to prevent dehydration.

• Multidisciplinary Follow-Up: This is the cornerstone of success. A structured program with surgeons, dietitians, and specialists is mandatory to manage the device and mitigate the high probability of weight regain after removal.

• Combination Therapy: Combining balloon therapy with GLP-1 agonists (sequentially or concomitantly) is an emerging strategy to enhance weight loss and prevent rebound weight gain.

3. Duodenal Mucosal Resurfacing (DMR) and Endoscopic Duodenal Therapies

3.1. The Foregut Hypothesis

The duodenum is a key metabolic regulator. The "Mucosal Abnormality Hypothesis" posits that chronic exposure to unhealthy diets causes pathological changes in the duodenal mucosa (inflammation, hypertrophy), leading to altered neurohormonal signaling and insulin resistance. DMR aims to ablate this pathological tissue, allowing for regeneration of a healthy mucosal layer and a "reset" of metabolic function.

3.2. Procedural Techniques

These procedures ablate the duodenal mucosa from the second portion to the ligament of Treitz, carefully avoiding the ampulla of Vater.

• Hydrothermal Ablation (Revita DMR): Uses a balloon catheter to circulate heated saline (90°C) to ablate the mucosa after a protective submucosal saline lift.

• Electroporation (Reset): A non-thermal technique using electrical pulses to induce apoptosis in mucosal cells, potentially offering an enhanced safety profile.

• Radiofrequency (RF) Vapor Ablation: A through-the-scope technique using vaporized saline to deliver thermal energy, avoiding the need for fluoroscopy.

3.3. Efficacy and Applications

• Glycemic Control: Clinical trials consistently demonstrate a durable, weight-loss-independent reduction in HbA1c of 0.8% to 1.6%.

• NAFLD: The intragastric balloon has an FDA-approved indication for managing non-alcoholic fatty liver disease (NAFLD), and DMR has also shown improvements in liver steatosis.

• GLP-1 "Off-Ramp" (REMAIN-1 Study): A groundbreaking application for DMR is its use to maintain weight loss and prevent weight regain after discontinuing GLP-1 agonist therapy. Preliminary data are promising.

4. Endoscopic Sleeve Gastroplasty (ESG)

4.1. Principles and Mechanism of Action

ESG is a primary endobariatric therapy that functionally mimics a laparoscopic sleeve gastrectomy without incisions or organ removal.

• Mechanism: Using a full-thickness endoscopic suturing device (e.g., OverStitch), a series of sutures are placed along the greater curvature of the stomach. When cinched, these sutures plicate the gastric wall, remodeling the stomach into a narrow, restrictive tube.

• Effects: The procedure provides mechanical restriction, delays gastric emptying, and induces favorable hormonal changes (e.g., increased GLP-1, PYY) that enhance satiety.

4.2. Operative Principles

• Full-Thickness Bites: This is the most critical principle for durability. The suture must capture the serosa to create a strong, lasting serosa-to-serosa apposition.

• Suture Pattern and Placement: Sutures are placed in systematic patterns (e.g., U, I, or Z patterns) to create a continuous "wall of suture" from the antrum to the fundus, ensuring uniform plication.

• Tissue Management: The surgeon must manage gastric volume during plication to avoid excessive tension, which can lead to tissue strangulation and suture erosion ("cheese-wiring").

4.3. Efficacy and Patient Selection

• Efficacy: ESG consistently achieves a TBWL of 15-20% and an excess weight loss (EWL) of 50-70%. Long-term data shows good durability at 5 years.

• Safety: ESG has a very low rate of serious adverse events. Unlike surgical sleeve, it rarely causes or worsens GERD.

• Patient Selection (IFSO 2024 Statement): ESG is endorsed for patients with Class I (BMI 30-34.9) and Class II (BMI 35-39.9) obesity. It is also a viable option for select patients with Class III obesity (BMI ≥ 40) who decline or are not candidates for surgery.

• Combination Therapy: ESG combined with GLP-1 agonists has shown synergistic results, with TBWL approaching 25%, rivaling some surgical outcomes.

SURGICAL PEARLS

• Intragastric Balloon: For removal, always use endotracheal intubation to protect the airway. Puncture the balloon in a forward view for stability, but grasp it in a retroflexed view for a better angle. Lubricate the deflated balloon with oil to ease withdrawal.

• DMR: A successful submucosal saline lift is critical during hydrothermal ablation to create a protective cushion and prevent deep thermal injury to the duodenal wall.

• ESG Full-Thickness Bite: The key visual cue is creating a clean "tent" of gastric wall after engaging the tissue with the Helix device. This confirms a full-thickness purchase without incorporating extra-gastric structures.

• ESG Suture Placement: Visualize a straight line for your suture path. Consistent alignment of bites ensures the stomach cinches down uniformly. Avoid excessive tension to prevent the "cheese-wire" effect.

• Skill Development for Trainees: Practice one-handed endoscopy on routine cases. Use your non-dominant hand for tip deflection and torque, freeing your dominant hand to operate therapeutic devices. This is a non-negotiable skill for endoluminal surgery.

ANESTHETIC AND PHYSIOLOGICAL CONSIDERATIONS

• Intragastric Balloon Removal: General anesthesia with endotracheal intubation is strongly recommended. The presence of the balloon can lead to retained gastric contents despite pre-procedural fasting, creating a significant aspiration risk.

• GERD after ESG: ESG has been observed to rarely worsen pre-existing GERD and may even improve it in some patients. This is a significant advantage over laparoscopic sleeve gastrectomy, where de novo GERD is a known concern. The preservation of some fundal accommodation may contribute to this effect.

COMPLICATIONS AND THEIR MANAGEMENT

• Intraoperative

  • ESG/DMR: Risks include bleeding and perforation, which are typically managed endoscopically. Inadequate submucosal lift during DMR can cause deep thermal injury.

• Early Postoperative

  • Intragastric Balloon: Severe nausea, vomiting, and dehydration are common. Manage with aggressive antiemetics and IV hydration. Pain persisting beyond one week requires urgent re-evaluation.

  • DMR: Abdominal pain and transient GI bleeding are typically self-limiting. Acute pancreatitis is a rare but serious risk.

• Late Postoperative

  • Intragastric Balloon: Spontaneous deflation with distal small bowel obstruction is a surgical emergency. Pressure ulceration and balloon corrosion from fungal colonization can occur, requiring endoscopic intervention.

  • DMR: Duodenal stricture formation is an uncommon risk that may require endoscopic balloon dilation.

  • ESG: Suture erosion or plication failure leading to weight regain can occur.

MEDICOLEGAL AND PATIENT SELECTION CONSIDERATIONS

• Physician Responsibility: The placement of any endoscopic bariatric device, particularly temporary ones like the intragastric balloon, imparts a significant medicolegal responsibility on the physician to provide continuous and thorough follow-up for the entire duration the device is in situ.

• Informed Consent: Patients must understand that these procedures are powerful "tools," not "cures." Success is contingent upon their active participation in a comprehensive, multidisciplinary program involving diet, exercise, and behavior modification.

• Setting Expectations: It is crucial to provide realistic expectations regarding weight loss outcomes for each procedure. ESG is highly effective but generally less potent than surgical bypass or sleeve. DMR's primary benefit is metabolic, with only modest weight loss.

• Expanding Practice: Offering ESG can serve as an effective gateway to comprehensive bariatric care. Many patients initially seeking a less invasive option may, after counseling, opt for traditional surgery.

• Reimbursement: The anticipated establishment of CPT codes and insurance coverage for procedures like ESG will dramatically increase patient access but will also heighten the need for standardized training and quality assurance.

SUMMARY AND TAKE-HOME MESSAGES

• Endobariatric therapies, including intragastric balloons, DMR, and ESG, represent a vital and expanding pillar in the comprehensive management of obesity and metabolic disease.

• The intragastric balloon is a temporary tool whose success is critically dependent on a robust multidisciplinary program and post-removal strategies to prevent weight regain.

• ESG is a durable, safe, and effective primary bariatric procedure that remodels gastric anatomy, bridges the gap between medical and surgical therapy, and achieves a TBWL of 15-20%.

• DMR is a promising, disease-modifying therapy that targets the pathophysiology of type 2 diabetes at its origin in the duodenum, offering weight-loss-independent metabolic benefits.

• The future of advanced obesity care lies in combination therapy, pairing procedural and pharmacological interventions to achieve superior and more durable results.

MULTIPLE CHOICE QUESTIONS (MCQs)

1. What is the primary mechanism by which Endoscopic Sleeve Gastroplasty (ESG) induces weight loss?

   a) Malabsorption of fat and carbohydrates

   b) Gastric restriction via plication of the greater curvature

   c) Temporary space occupation of the gastric fundus

   d) Ablation of ghrelin-producing mucosa

2. According to the "foregut hypothesis," what is the primary goal of Duodenal Mucosal Resurfacing (DMR)?

   a) To create a bypass of the duodenum to limit caloric absorption

   b) To significantly slow gastric emptying into the small intestine

   c) To ablate pathological mucosa and allow regeneration of healthy tissue, restoring normal metabolic signaling

   d) To place a restrictive stent in the duodenal bulb

3. What is the recommended anesthetic practice for the removal of a liquid-filled intragastric balloon?

   a) Local anesthetic spray only

   b) Conscious sedation

   c) General anesthesia with endotracheal intubation

   d) No anesthesia or sedation required

4. Which medication was highlighted as being significantly more potent than ondansetron for managing post-intragastric balloon nausea?

   a) Dimenhydrinate

   b) Scopolamine

   c) Aprepitant

   d) Metoclopramide

5. The MERIT randomized controlled trial demonstrated the superiority of ESG over lifestyle modification for which patient population?

   a) Class III obesity (BMI ≥ 40)

   b) Class I obesity (BMI 30-34.9)

   c) Patients with uncontrolled type 2 diabetes

   d) Adolescents with severe obesity

6. According to the large-scale Brazilian consensus data, what was the mean total body weight loss (TBWL) achieved with intragastric balloons?

   a) 7.5%

   b) 12.1%

   c) 18.4%

   d) 24.3%

7. What is the most critical technical principle for ensuring the long-term durability of an ESG procedure?

   a) Using a Z-pattern suture in all cases

   b) Achieving full-thickness, serosa-to-serosa suture bites

   c) Limiting the procedure time to under 60 minutes

   d) Placing sutures at least 4 cm apart

8. Which endoscopic duodenal therapy is described as a non-thermal technique that induces apoptosis?

   a) Hydrothermal ablation (Revita DMR)

   b) Radiofrequency vapor ablation

   c) Electroporation (Reset)

   d) Argon plasma coagulation

9. Combining ESG with a GLP-1 agonist has been shown to achieve a TBWL of approximately:

   a) 15%

   b) 18%

   c) 21%

   d) 25%

10. What is a key advantage of the RF vapor ablation system for duodenal treatment?

    a) It is a non-thermal energy source

    b) It is the only system approved for obesity

    c) It is a through-the-scope procedure that does not require fluoroscopy

    d) It guarantees a 2% reduction in HbA1c

11. A deflated intragastric balloon that migrates and causes a blockage is an example of what complication?

    a) Gastric outlet obstruction

    b) Esophageal perforation

    c) Distal small bowel obstruction

    d) Acute pancreatitis

12. The REMAIN-1 clinical trial is investigating DMR as a potential "off-ramp" to maintain weight loss after discontinuing which class of medication?

    a) Proton pump inhibitors

    b) GLP-1 receptor agonists

    c) Oral hypoglycemics

    d) Statins

13. According to the 2024 IFSO statement, ESG is an endorsed intervention for which obesity classes?

    a) Class III only

    b) Class I only

    c) Class I and Class II

    d) All classes of obesity without restriction

14. What endoscopic skill is considered essential for trainees to master for performing complex endoluminal surgery like ESG?

    a) Rapid esophageal intubation

    b) One-handed scope manipulation to free the dominant hand

    c) Proficiency in colonoscopy

    d) Consistent retroflexion in the gastric cardia

15. What is the primary advantage of an adjustable gastric balloon (e.g., Spatz3)?

    a) It does not require endoscopy for placement

    b) Its volume can be modified post-placement to manage tolerance or improve efficacy

    c) It can be left in the stomach indefinitely

    d) It is filled with gas, making it lighter

16. How does ESG typically affect Gastroesophageal Reflux Disease (GERD)?

    a) It consistently cures GERD by tightening the lower esophageal sphincter

    b) It almost always causes severe, de novo GERD

    c) It has no effect on GERD symptoms

    d) It rarely worsens GERD and may improve it in some patients

17. What is the recommended management for the common initial symptoms of nausea and dehydration after intragastric balloon placement?

    a) Immediate endoscopic removal of the balloon

    b) A liquid-only diet for one month

    c) Aggressive antiemetics and proactive IV hydration within 48 hours

    d) Advising the patient to tolerate the symptoms, as they are normal

18. What is the primary mechanism of action of a swallowable balloon system?

    a) It is endoscopically placed and then dissolves over time

    b) It is surgically implanted and removed via laparoscopy

    c) It is swallowed, inflates in the stomach, and later deflates via a self-releasing valve for natural excretion

    d) It attaches permanently to the gastric wall

19. In the conceptual framework presented, which component of obesity management does ESG primarily address?

    a) The "operator" (patient behavior) only

    b) The "software" (hormones) only

    c) Both the "hardware" (gastric anatomy) and "software" (hormones)

    d) The "fuel" (diet) only

20. A key step during hydrothermal DMR to protect the deeper layers of the duodenal wall is:

    a) Administering IV glucagon

    b) Performing a submucosal saline lift

    c) Cooling the ablation balloon to 0°C

    d) Placing a temporary stent across the ampulla

Answer Key: 1-b, 2-c, 3-c, 4-c, 5-b, 6-c, 7-b, 8-c, 9-d, 10-c, 11-c, 12-b, 13-c, 14-b, 15-b, 16-d, 17-c, 18-c, 19-c, 20-b

MOTIVATIONAL MESSAGE FROM DR. R. K. MISHRA

The pursuit of surgical excellence is a journey without a final destination. Each procedure is a new beginning, an opportunity to refine your skill, deepen your understanding, and reaffirm your commitment to the life entrusted to your hands.

My very best wishes to all of you as you continue on this noble path of learning, service, and compassionate care.